3-[5-[(E)-[[2-[2-nitro-4-(2,4,4-trimethylpentan-2-yl)phenoxy]acetyl]hydrazinylidene]methyl]furan-2-yl]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[5-[(E)-[[2-[2-nitro-4-(2,4,4-trimethylpentan-2-yl)phenoxy]acetyl]hydrazinylidene]methyl]furan-2-yl]benzoic acid
• 化学式: C28H31N3O7
• 分子量: 521.6
• InChiKey: JWRJOZSTYWEVPK-WKULSOCRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  147
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Use of Pde1c and Inhibitors Thereof
  申请人：Dunkern Torsten

  公开号：US20090030065A1

  公开（公告）日：2009-01-29

  The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1C inhibitors in the manufacture of pharmaceutical compositions for use in the therapy of those diseases.
• [EN] USE OF PDE1C AND INHIBITORS THEREOF<br/>[FR] UTILISATION DE PDE1C ET INHIBITEURS DE CELUI-CI
  申请人：ALTANA PHARMA AG

  公开号：WO2006134101A2

  公开（公告）日：2006-12-21

  [EN] The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1 C inhibitors in the manufacture of pharmaceutical compositions for use in the therapy of those diseases.
  [FR] La présente invention concerne l'utilisation de PDE1C comme nouvelle cible pour l'identification de composés, qui peut être utilisé pour le traitement de l'hypertension pulmonaire, des pneumopathies fibrosantes et d'autres maladies fibrosantes hors des poumons. Cette invention concerne aussi l'utilisation d'inhibiteurs de PDE1 C dans la fabrication de compositions pharmaceutiques destinées à la thérapie de ces maladies.